ReviewUnited European gastroenterology journal2020
Natural history, diagnosis and treatment approach to fibrostenosing Crohn's disease.
Review in United European gastroenterology journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- The missing evidence: Stricturing Crohn's disease in clinical trials, a systematic review.Inflammatory bowel diseases · 2026Pooled it
- Anastomotic configurations and early endoscopic recurrence following ileocolonic resection in Crohn's disease: systematic review and meta-analysis.International journal of colorectal disease · 2026Pooled it
- Duodenal stricture in Crohn's disease successfully managed with a fully covered metal stent-assisted with double pig-tail stents.Endoscopy · 2025Trial
- Mast cell-derived IL-13 as a driver of Crohn disease-associated intestinal fibrosis.Inflammatory bowel diseases · 2026Article
- Beyond the Intestinal Mucosa in Long-Standing Inflammatory Bowel Disease: Consequences of Chronic Inflammation and Endoscopic Approaches to Diagnosis and Management.Medicina (Kaunas, Lithuania) · 2026Review
- Endoscopic stricture management in inflammatory bowel disease: Present and future.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2026Review
- Vedolizumab for stricturing Crohn's disease of the terminal ileum - an international multicenter cohort study.BMC gastroenterology · 2026Observational
- Terminal Ileal Ulcers: Endoscopic Predictors for the Later Development of Crohn's Disease.Diagnostics (Basel, Switzerland) · 2026Article
- Rethinking risk in Crohn's surgery: age at onset fails to predict surgical outcomes after ileocecal resection, insights from a tertiary referral center.Techniques in coloproctology · 2026Article
- The exosomal miR-26b-3p derived from Crohn's disease-associated mesenteric adipose tissue induces M1 macrophage polarization and exacerbates ileocolonic anastomosis inflammation via the p38-MAPK signaling pathway.Frontiers in immunology · 2026Article
- Recent insights into the roles and therapeutic potentials of GLS1 in inflammatory diseases.Journal of pharmaceutical analysis · 2025Review
- SAR Consensus Recommendations for Defining Small Bowel Crohn Disease Strictures at CT and MR Enterography.Radiology · 2025Review
- Surgery time for stenosed Crohn's disease: Case report.International journal of surgery case reports · 2025Article
- Radiomics to Detect Inflammation and Fibrosis on Magnetic Resonance Enterography in Stricturing Crohn's Disease.Journal of Crohn's & colitis · 2024Article
- Imaging and clinical predictors of surgery in stricturing ileal Crohn's disease: a retrospective study from a large pediatric hospital.Abdominal radiology (New York) · 2024Article
- Muscular hyperplasia in Crohn's disease strictures: through thick and thin.American journal of physiology. Cell physiology · 2024Review
- Inflammatory Bowel Disease: Immune Function, Tissue Fibrosis and Current Therapies.International journal of molecular sciences · 2024Article
- Fibrostenosing Crohn's Disease: Pathogenetic Mechanisms and New Therapeutic Horizons.International journal of molecular sciences · 2024Review
- Interventional endoscopy in inflammatory bowel disease: a comprehensive review.Gastroenterology report · 2024Review
- Crohn's disease and clinical management today: How it does?World journal of methodology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Stricturing Crohn's disease (CD) is a significant clinical problem. The presence of a stricture may be suggested by clinical symptoms. Cross-sectional imaging using computed tomography or magnetic resonance enterography is essential in diagnosing strictures as it allows further characterization and evaluation for complications such as abscess, fistulizing disease or malignancy. Managing small bowel stricturing CD should be approached in a multidisciplinary fashion. Medical therapy can be considered in strictures which are not associated with complications, with most of the data supporting anti-TNF strategies in this setting. If the disease is refractory to medical therapy, endoscopic therapy or surgery should be performed. Endoscopic balloon dilation (EBD) is an option for short, uncomplicated and straight strictures that are within reach of a colonoscope. Although EBD has good short-term outcomes, repeat dilation is often required. Surgical options mainly include resection and strictureplasty. Strictures refractory to medical therapy, not amenable or refractory to EBD, or associated with complications or malignancy should be managed surgically. However, surgery may also be considered at an earlier stage depending on disease characteristics and patient preference. Postoperative recurrence is common, highlighting the importance of careful monitoring of the patient postoperatively and optimization of medical management accordingly. There is a pressing need to develop anti-fibrotics for the treatment of stricturing CD. This requires the development of standardized diagnostic criteria, patient-reported outcome measures and validation of endpoints in fibrostenotic CD. The STAR consortium is pioneering this effort in order to allow development and testing of anti-fibrotics in future clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.